- Preparation method of key intermediate of saxagliptin
-
The invention relates to a preparation method of (1S, 3S, 5S)-3-(amidogen carbonyl)-2- azabicyalo [3.1.0] hexane-2-tert-butyl formate. The preparation method comprises the following steps that (1), Boc-L-pyroglutamic acid methyl ester is restored through lithium triethylborohydride and then dewatered through trifluoroacetic anhydride to obtain (S)-1-N-tert-butyloxycarbonyl-2,3-dihydro-2-pyrrole ethyl formate; (2), DIPEA is added in the hydrolysis reaction of (S)-1-N-tert-butyloxycarbonyl-2,3-dihydro-2-pyrrole ethyl formate under a alkaline condition, then salifying is conducted, and (S)-1-N-tert-butyloxycarbonyl-2,3-dihydro-2-pyrrole formic acid N, N-diisopropyl ethylamine salt is obtained; (3), (S)-1-N-tert-butyloxycarbonyl-2,3-dihydro-2-pyrrole formic acid N and N-diisopropyl ethylamine salt obtained in the step (2) are subjected to amidating, and (S)-1-N- tert-butyloxycarbonyl-2,3-dihydro-2-pyrrole formamide is obtained; and (4), (S)-1-N-tert-butyloxycarbonyl-2,3-dihydro-2-pyrrole formamide is catalyzed through a chirality nickel catalyst and subjected to a ciprofloxacin reaction, and a target material with single configuration, namely (1S, 3S, 5S)-3-(amidogen carbonyl)-2-azabicyalo [3.1.0] hexane-2-tert-butyl formate (SM1), is obtained.
- -
-
-
- Method for preparing saxagliptin intermediates
-
The invention discloses a method for preparing saxagliptin intermediate compounds. The method includes steps of carrying out reaction on compounds I and dibromomethane in ether organic solvents in the presence of acid under the catalytic effects of cuprous catalysts and zinc powder to obtain the saxagliptin intermediate compounds. The method has the advantages of low cost, little environmental pollution, simplicity and convenience in operation and applicability to industrialization.
- -
-
Paragraph 0140-0142
(2017/08/31)
-
- PROCESS FOR PREPARING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREFOR
-
A process for preparing an amine of the structure which comprises a. treating an aqueous solution of a keto acid of the structure with ammonium formate, nicotinamide adenine dinucleotide, dithiothreitol and partially purified phenylalanine dehydrogenase and/or formate dehydrogenase enzyme (PDH/FDH); and b. adjusting pH of the reaction mixture with sodium hydroxide to form the desired amine which is substantially free of undesirable excess ammonium ions.
- -
-
-
- An cost-effective and safe process of L-cis-4,5-methanoproline amide, the key synthetic intermediate of saxagliptin, via an improved Simmons-Smith reaction
-
L-cis-4,5-Methanoproline amide, a key intermediate of saxagliptin, was synthesized by an improved Simmons-Smith reaction. The zinc carbenoid was formed through Zn/CuBr and CH2I2, under the optimized condition, the title compound was gained with 68% yield and excellent diastereomeric selectivity (40:1 d.r.). The absence of the flammable and expensive ZnEt2 makes this procedure very attractive in large scale production.
- Ding, Ding,Pan, Xianhua,Yu, Wansheng,Li, Xiaojun,Chen, Suke,Liu, Feng
-
p. 719 - 726
(2015/05/05)
-
- Protected amino hydroxy adamantane carboxylic acid and process for its preparation
-
Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided. The provided compounds can be used for treating diabetes and related diseases, especially Type II diabetes, and other diseases as set out herein, employing such DP 4 inhibitor or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity agent and/or other therapeutic agent.
- -
-
-
- The effect of additives on the zinc carbenoid-mediated cyclopropanation of a dihydropyrrole
-
The synthesis of a key intermediate in the preparation of oral antidiabetic drug Saxagliptin is discussed with an emphasis on the challenges posed by the cyclopropanation of a dihydropyrrole. Kinetic studies on the cyclopropanation show an induction period that is consistent with a change in the structure of the carbenoid reagent during the course of the reaction. This mechanistic transition is associated with an underlying Schlenk equilibrium that favors the formation of monoalkylzinc carbenoid IZnCH2I relative to dialkylzinc carbenoid Zn(CH2I)2, which is responsible for the initiation of the cyclopropanation. The factors influencing reaction rates and diastereoselectivities are discussed with the aid of DFT computational studies. The rate accelerations observed in the presence of Br?nsted acid-type additives correlate with the minimization of the undesired induction period and offer insights for the development of a robust process.
- Ramirez, Antonio,Truc, Vu Chi,Lawler, Michael,Ye, Yun K.,Wang, Jianji,Wang, Chenchi,Chen, Steven,Laporte, Thomas,Liu, Nian,Kolotuchin, Sergei,Jones, Scott,Bordawekar, Shailendra,Tummala, Srinivas,Waltermire, Robert E.,Kronenthal, David
-
p. 6233 - 6243
(2014/07/21)
-
- Synthesis and biological evaluation of all eight stereoisomers of DPP-IV inhibitor saxagliptin
-
All eight stereoisomers of saxagliptin have been synthesized and evaluated for their inhibitory activity against DPP-IV. It was unambiguously confirmed that the configuration of saxagliptin was critical to potent inhibition of DPP-IV. Docking study was performed to elucidate the configuration-activity relationship of saxagliptin stereoisomers. Tyr662 and Tyr470 have been suggested as the key residues of DPP-IV interacting with the inhibitors. This work provides valuable information for further inhibitor design against DPP-IV.
- Dong, Jizhe,Gong, Yanchun,Liu, Jun,Chen, Xiangfeng,Wen, Xiaoan,Sun, Hongbin
-
p. 1383 - 1393
(2014/03/21)
-
- Ammonolysis process for the preparation of intermediates for DPP IV inhibitors
-
A process is provided for preparing the intermediate A in accordance with the following reaction sequence The intermediate A is used in preparing DPP IV inhibitors which are useful in treating diabetes.
- -
-
Page/Page column 6-7
(2010/10/19)
-
- DIPEPTIDYL PEPTIDASE-IV INHIBITORS
-
The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes.
- -
-
Page/Page column 114-116
(2008/06/13)
-
- Synthesis of Novel Potent Dipeptidyl Peptidase IV Inhibitors with Enhanced Chemical Stability: Interplay between the N-Terminal Amino Acid Alkyl Side Chain and the Cyclopropyl Group of α -Aminoacyl-L-cis-4,5-methanoprolinenitrile-Based Inhibitors
-
A series of methanoprolinenitrile-containing dipeptide mimetics were synthesized and assayed as inhibitors of the N-terminal sequence-specific serine protease dipeptidyl peptidase IV (DPP-IV). The catalytic action of DPP-IV is the principle means of degradation of glucagon-like peptide-1, a key mediator of glucose-stimulated insulin secretion, and DPP-IV inhibition shows clinical benefit as a novel mechanism for treatment of type 2 diabetes. However, many of the reversible inhibitors to date suffer from chemical instability stemming from an amine to nitrile intramolecular cyclization. Installation of a cyclopropyl moiety at either the 3,4- or 4,5-position of traditional 2-cyanopyrrolidide proline mimetics led to compounds with potent inhibitory activity against the enzyme. Additionally, cis-4,5-methanoprolinenitriles with β-branching in the N-terminal amino acid provided enhanced chemical stability and high inhibitory potency. This class of inhibitors also exhibited the ability to suppress prandial glucose elevations after an oral glucose challenge in male Zucker rats.
- Magnin, David R.,Robl, Jeffrey A.,Sulsky, Richard B.,Augeri, David J.,Huang, Yanting,Simpkins, Ligaya M.,Taunk, Prakash C.,Betebenner, David A.,Robertson, James G.,Abboa-Offei, Benoni E.,Wang, Aiying,Cap, Michael,Xin, Li,Tao, Li,Sitkoff, Doree F.,Malley, Mary F.,Gougoutas, Jack Z.,Khanna, Ashish,Huang, Qi,Han, Song-Ping,Parker, Rex A.,Hamann, Lawrence G.
-
p. 2587 - 2598
(2007/10/03)
-
